MouseBIRN.AlzheimerDM (r1.1 vs. r1.2)
Diffs

 <<O>>  Difference Topic AlzheimerDM (r1.2 - 10 Oct 2005 - JylBoline)

META TOPICPARENT MouseBIRNIndividualProjects
Changed:
<
<

Parkinson’s Disease, the Alpha Synuclein Mouse Model

The project efforts are focused on the development and application of correlated imaging approaches (confocal and electron microscopy, in vivo microscopic MRI) to Parkinson's disease (PD)—applied first to recently generated transgenic animal models of PD. Knowledge gained from this project will facilitate the assessment of neuropathologies and effectiveness of possible chemotherapeutic treatments for PD.
>
>

Alzheimer’s Disease, Tet-off APP Transgenic Mouse Model

Alzheimer's disease is thought to arise from the accumulation of a small peptide termed amyloid-beta that is normally found in healthy individuals, but is abnormally abundant in the brains of AD patients. The peptide aggregates into extracellular lesions or amyloid plaques that are found throughout the hippocampus and cortex of affected individuals. Both amyloid pathology and the cognitive decline associated with AD can be recreated in transgenic mouse models for the disease. Mice overexpressing the human amyloid precursor protein (APP) with mutations identified from families with inherited AD generate high levels of amyloid-beta and form amyloid plaques similar to those used found in the brains of patients with AD.

Changed:
<
<		 The overall goals for this project are to:

1. Characterize the phenotypic differences between transgenic alpha synuclein and wildtype mice at three levels:

  • Gross level
  • Regional/cellular level
  • High resolution distribution maps of molecular constituents

2. Integrate multi-scale data into the BIRN

3. Establish collaborations with other groups and bring additional PD models for comparison

>
>		 The mouse BIRN will examine a transgenic mouse model for AD in which the expression of APP can be controlled with antibiotic treatment. We anticipate that this controllable transgenic mouse model can be used with MRI and the other methods employed by collaborators in the mouse BIRN to study the long-term kinetics of amyloid lesions in the brain under conditions similar to those expected from future AD therapies.


 <<O>>  Difference Topic AlzheimerDM (r1.1 - 27 Jul 2005 - JylBoline)
Line: 1 to 1
Added:
>
>
META TOPICPARENT MouseBIRNIndividualProjects

Parkinson’s Disease, the Alpha Synuclein Mouse Model

The project efforts are focused on the development and application of correlated imaging approaches (confocal and electron microscopy, in vivo microscopic MRI) to Parkinson's disease (PD)—applied first to recently generated transgenic animal models of PD. Knowledge gained from this project will facilitate the assessment of neuropathologies and effectiveness of possible chemotherapeutic treatments for PD.

The overall goals for this project are to:

1. Characterize the phenotypic differences between transgenic alpha synuclein and wildtype mice at three levels:

  • Gross level
  • Regional/cellular level
  • High resolution distribution maps of molecular constituents

2. Integrate multi-scale data into the BIRN

3. Establish collaborations with other groups and bring additional PD models for comparison


Topic: AlzheimerDM . { View | Diffs | r1.2 | > | r1.1 | More }

Revision r1.1 - 27 Jul 2005 - 21:31 - JylBoline
Revision r1.2 - 10 Oct 2005 - 19:16 - JylBoline